This strategic play will take time to pay off, but it could keep growth going. On Sept. 16 Novo Nordisk (NVO 0.04%) and Korro Bio (KRRO -1.45%) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most would assume to be Moderna's (MRNA -2.96%) home territory. It's natural for investors to wonder if the competitive landscape in biopharma may have changed in a big way. And it might -- but probably not in the way that some are expecting. ...